V. Diehl

发表

T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group

A. Rosenwald, R. Greil, H. Eich, 2022, HemaSphere.

Hodgkin's cell lines: Characteristics and possible pathogenetic implications

V. Diehl, J. Gerdes, C. Fonatsch, 2007, Hematological oncology.

A possible correlation between the degree of karyotype aberrations and the rate of sister chromatid exchanges in lymphoma lines

C. Fonatsch, H. Kirchner, M. Schaadt, 1980, International journal of cancer.

Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient.

V. Diehl, K. Rajewsky, R. Küppers, 1996, Blood.

Deregulation of immunoglobulin gene transcription in the Hodgkin–Reed Sternberg cell line L1236

V. Diehl, U. Holtick, D. Ré, 2001, British journal of haematology.

Lack of BCL10 mutations in Hodgkin's disease‐derived cell lines

V. Diehl, D. Ré, J. Wolf, 2000, British journal of haematology.

Patterns of DNA methylation in selected human genes in different Hodgkin's lymphoma and leukemia cell lines and in normal human lymphocytes.

V. Diehl, H. Tesch, W. Doerfler, 1991, Cancer research.

Heterogeneous expression of proto‐oncogenes in Hodgkin's disease derived cell lines

V. Diehl, H. Tesch, S. Poppema, 1990, Hematological oncology.

Prognostic factors in idiopathic (Primary) osteomyelofibrosis

R. Fischer, J. Thiele, H. Kvasnicka, 1997, Cancer.

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

J. Armitage, V. Diehl, T. Lister, 1998, The New England journal of medicine.

Standardization of bone marrow features--does it work in hematopathology for histological discrimination of different disease patterns?

H M Kvasnicka, V. Diehl, J. Thiele, 2005, Histology and histopathology.

Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML

V. Diehl, J. Franklin, H. Tesch, 1999, Annals of Hematology.

V. Diehl, J. Thiele, A. Schmitt-Gräff, 2004, Histology and histopathology.

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.

V. Diehl, B. Dörken, M. Sieber, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups.

V. Diehl, G. Klein, A. D. Schryver, 1970, Journal of the National Cancer Institute.

Polycythemia rubra vera versus secondary polycythemias. A clinicopathological evaluation of distinctive features in 199 patients.

V. Diehl, J. Thiele, H. Kvasnicka, 2001, Pathology, research and practice.

Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma

V. Diehl, L. Gissmann, H. zur Hausen, 1982, Journal of virology.

No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group.

V. Diehl, S. Hofer, P. Borchmann, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells.

C. von Kalle, V. Diehl, C. Schoch, 1996, Blood.

European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes.

V. Diehl, N. Harris, E. Jaffe, 2000, Blood.

Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.

V. Diehl, A. Bernareggi, P. Staib, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

V. Diehl, B. Coiffier, J. Radford, 1998, Blood.

Epidemiology and etiology of Hodgkin's lymphoma.

V. Diehl, T. Zander, R. Thomas, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Artificial sweeteners--do they bear a carcinogenic risk?

V. Diehl, M R Weihrauch, V Diehl, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection.

V. Diehl, M. Sieber, B. Salzberger, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial.

V. Diehl, P. Borchmann, M. von Wolff, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.

V. Diehl, N. Harris, E. Jaffe, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

T-cell Non-Hodgkin's Lymphoma in Adults: Clinicopathological Characteristics, Response to Treatment and Prognostic Factors

V. Diehl, B. Salzberger, P. Staib, 2002, Leukemia & lymphoma.

Human chronic lymphocytic leukemia cells regularly express mRNAs of the protooncogenes lck and c-fgr.

H Tesch, V. Diehl, H. Tesch, 1991, Leukemia research.

STAT3 is constitutively activated in Hodgkin cell lines.

V. Diehl, H. Tesch, P. Heinrich, 2001, Blood.

European Code Against Cancer and scientific justification: third version (2003).

H. Bartelink, R. Doll, M. Kogevinas, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group.

H. Eich, R. Müller, V. Diehl, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography.

V. Diehl, H. Tesch, H. Bohlen, 1997, Journal of immunological methods.

Early, intermediate and advanced Hodgkin's lymphoma: modern treatment strategies.

V. Diehl, M. Fuchs, V. Diehl, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of Epstein-Barr Virus Nuclear Antigen 1 Is Associated with Enhanced Expression of CD25 in the Hodgkin Cell Line L428

V. Diehl, E. Kieff, H. Tesch, 1999, Journal of Virology.

Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions.

H. Eich, V. Diehl, P. Borchmann, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Classical Hodgkin's disease. Clinical impact of the immunophenotype.

V. Diehl, K. Hübner, J. Franklin, 1997, The American journal of pathology.

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)

V. Diehl, A. Engert, M. Jensen, 2016 .

Treatment of Hodgkin's disease: results and current concepts of the German Hodgkin's Lymphoma Study Group.

V. Diehl, M. Sieber, A. Engert, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.

M Sieber, A Engert, H. Eich, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group.

V. Diehl, M. Pfreundschuh, B. Lathan, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease

B. Krug, V. Diehl, J. Franklin, 2001, Annals of Hematology.

Expression of AC133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells.

V. Diehl, H. Tesch, D. Voliotis, 1999, Blood.

Hodgkin and Reed-Sternberg cells express interleukin 6 and interleukin 6 receptors.

V. Diehl, H. Tesch, M. Jücker, 1992, Leukemia & lymphoma.

Sister chromatid exchange in cell lines from malignant lymphomas (lymphoma lines)

V. Diehl, C. Fonatsch, M. Schaadt, 1979, Human Genetics.

Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.

V. Diehl, H. Tesch, M. Dietlein, 2001, Blood.

Interleukin 10 inhibits cytokine production of human AML cells.

V. Diehl, F. Westermann, H. Tesch, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T‐cell leukemia and infectious mononucleosis

V. Diehl, A. Tschiersch, C. Pohl, 1990, International journal of cancer.

Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF.

V. Diehl, N. Schmitz, J. Franklin, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group.

V. Diehl, J. Franklin, M. Sieber, 2000, Blood.

Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).

V. Diehl, H. Tesch, A. Engert, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?

V. Diehl, B. Salzberger, M. Reiser, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New drugs in the treatment of Hodgkin's disease.

V. Diehl, P. Borchmann, R. Schnell, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30.

V. Diehl, H. Abken, C. Pohl, 1998, Cancer research.

Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? German Hodgkin Lymphoma Study Group.

V. Diehl, J. Franklin, U. Paulus, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.

V. Diehl, B. Dörken, Y. Ko, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).

V. Diehl, B. Dörken, M. Sieber, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin's disease from 1969 to 1994.

R. Greil, V. Diehl, G. Kemmler, 1999, European journal of cancer.

Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study

V. Diehl, G. Brittinger, D. Huhn, 2001, Annals of Hematology.

Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) – a clinicopathological study

V. Diehl, J. Thiele, R. Fischer, 1999, Leukemia.

Preliminary report: growth of Hodgkin's lymphoma derived cells in immune compromised mice.

C. von Kalle, V. Diehl, C. Fonatsch, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Lymphocyte-predominant Hodgkin's disease. An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study Group.

V. Diehl, K. Hübner, J. Franklin, 1997, The American journal of pathology.

Anti‐idiotype vaccine against Hodgkin's lymphoma: Induction of B‐ and T‐cell immunity across species barriers against cd30 antigen by murine monoclonal internal image antibodies

V. Diehl, M. Pfreundschuh, C. Pohl, 1992, International journal of cancer.

Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin

V. Diehl, V. Ghetie, S. Barth, 2000, Leukemia.

DIAGNOSTIC VALUE OF IMMUNOPHENOTYPING IN LOW‐GRADE B‐CELL LYMPHOMA

V. Diehl, F. Fend, C. Pohl, 1993, British journal of haematology.

A CD16/CD30 bispecific monoclonal antibody induces lysis of hodgkin's cells by unstimulated natural killer cells In AND In vivo

V. Diehl, M. Pfreundschuh, U. Şahin, 1993, International journal of cancer.

Treatment of Hodgkin's disease: current strategies of the German Hodgkin's Lymphoma Study Group.

V. Diehl, M. Sieber, U. Rüffer, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Occurrence of Epstein-Barr virus genomes in human lymphoblastoid cell lines.

V. Diehl, H. Hausen, U. Schneider, 1972, Nature: New biology.

Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.

V. Diehl, M. Pfreundschuh, P. Tazzari, 1990, Cancer research.

Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells.

V. Diehl, K. Rajewsky, R. Küppers, 2000, Cancer research.

Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells.

V. Diehl, U. Holtick, C. Wickenhauser, 2001, Cancer research.

Locoregional treatment of low‐grade B‐cell lymphoma with CD3×CD19 bispecific antibodies and CD28 costimulation: I. Clinical phase I evaluation

V. Diehl, H. Tesch, A. Gossmann, 2001, International journal of cancer.

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.

Bingshu E. Chen, H. Eich, V. Diehl, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

RELATION BETWEEN EPSTEIN-BARR VIRAL AND CELL MEMBRANE IMMUNOFLUORESCENCE IN BURKITT TUMOR CELLS

V. Diehl, G. Klein, W. Henle, 1968, The Journal of experimental medicine.

Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy

V. Diehl, H. Tesch, R. Schröder, 1999, Bone Marrow Transplantation.

Phase I study of intratumoral application of recombinant human tumor necrosis factor.

V. Diehl, M. Pfreundschuh, H. Steinmetz, 1989, European journal of cancer & clinical oncology.

Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma.

H. Eich, R. Müller, P. Borchmann, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunotoxins:Is there a clinical value?

H. Bohlen, A. Engert, C. Gottstein, 1994 .